# EDGAR Filing Document

**Accession Number:** 0001835205
**File Stem:** 0001104659-23-022265
**Filing Date:** 2023-2
**Character Count:** 9858
**Document Hash:** e32ed00e4f949cc33a3817c7fc49d6ec
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-022265.hdr.sgml**: 20230215

**ACCESSION NUMBER**: 0001104659-23-022265

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230215

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230215

**DATE AS OF CHANGE**: 20230215

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IBERE PHARMACEUTICALS
- **CENTRAL INDEX KEY:** 0001835205
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **IRS NUMBER:** 981564986
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40119
- **FILM NUMBER:** 23634130

**BUSINESS ADDRESS:**
- **STREET 1:** 2005 MARKET STREET, SUITE 2030
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19103
- **BUSINESS PHONE:** 267-765-3222

**MAIL ADDRESS:**
- **STREET 1:** 2005 MARKET STREET, SUITE 2030
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19103

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **February 15, 2023**

**Ibere Pharmaceuticals**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Cayman Islands** | **001-40119** | **98-1564986** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

**2005 Market Street, Suite 2030**

**Philadelphia, PA 19103**

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: **(267) 765-3222**

**Not Applicable** (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant | IBERU | New York Stock Exchange |
| Class A ordinary share, $0.0001 par value | IBER | New York Stock Exchange |
| Warrants, each whole warrant exercisable for one Class A ordinary share for $11.50 per share | IBERW | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 8.01.** | **Other Events** |

---

On February 15, 2023, Ibere Pharmaceuticals (the "Company" or "we") issued a press release announcing that it will redeem all of its outstanding ordinary shares that were included in the units issued in its initial public offering (the "public shares"), effective as of the close of business on March 2, 2023, as the Company will not consummate an initial business combination on or prior to March 2, 2023. We have attached hereto as Exhibit 99.1 a copy of the press release.

**Forward-Looking Statements**

Certain information contained in this press release may be deemed to constitute forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts for future events, including, without limitation, the redemption of the Company's public shares and the Company's subsequent dissolution and liquidation and its delisting from the New York Stock Exchange and its termination of registration with the Commission.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.** |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1](tm236640d1_ex99-1.htm) | [Press Release dated February 15, 2023.](tm236640d1_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **IBERE PHARMACEUTICALS** | **IBERE PHARMACEUTICALS** | **IBERE PHARMACEUTICALS** |
|  | By: | /s/ Osagie Imasogie | /s/ Osagie Imasogie |
|  |  | Name: | Osagie Imasogie |
|  |  | Title: | Chief Executive Officer |
| Dated: February 15, 2023 |  |  |  |

---

## Exhibit 99.1

**Exhibit 99.1**

FOR IMMEDIATE RELEASE

**Ibere Pharmaceuticals Announces Redemption of Public Shares and** 

**Subsequent Dissolution**

PHILADELPHIA, February 15, 2023 /PRNewswire/ — Ibere Pharmaceuticals (the "Company") today announced that it will redeem all of its outstanding ordinary shares that were included in the units issued in its initial public offering (the "Public Shares"), effective as of the close of business on March 2, 2023, as the Company will not consummate an initial business combination on or prior to March 2, 2023.

Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles"), in the event that either the Company does not consummate a business combination by twenty-four months after the closing of the Company's initial public offering (the "IPO"), or such later time as the members of the Company may approve in accordance with the Articles or a resolution of the Company's members is passed pursuant to the Companies Act (as amended) of the Cayman Islands to commence the voluntary liquidation of the Company prior to the consummation of a business combination for any reason, the Company shall: (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust fund, including interest earned on the trust fund and not previously released to the Company to pay income taxes, if any, (less up to $100,000 of interest to pay dissolution expenses), divided by the number of Public Shares then in issue, which redemption will completely extinguish public members' rights as members (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company's remaining members and the directors, liquidate and dissolve, subject in the case of sub-articles (ii) and (iii), to its obligations under Cayman Islands law to provide for claims of creditors and in all cases subject to the other requirements of applicable law.

The per-share redemption price for the Public Shares will be approximately $10.17.

The Public Shares will cease trading as of the close of business on March 1, 2023. As of the close of business on March 2, 2023, the Public Shares will be deemed cancelled and will represent only the right to receive the redemption amount.

The redemption amount will be payable to the holders of the Public Shares upon delivery of their shares or units. Beneficial owners of Public Shares held in "street name," however, will not need to take any action in order to receive the redemption amount.

There will be no redemption rights or liquidating distributions with respect to the Company's warrants, which will be terminated. The Company's initial shareholders have waived their redemption rights with respect to its outstanding common stock issued before the IPO.

The Company expects that the New York Stock Exchange will file a Form 25 with the United States Securities and Exchange Commission (the "Commission") to delist the Company's securities. The Company thereafter expects to file a Form 15 with the Commission to terminate the registration of its securities under the Securities Exchange Act of 1934, as amended.

**Forward-Looking Statements**

This press release may include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based on the beliefs and reasonable assumptions of management, and actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company's filings with the SEC. The Company undertakes no obligation to update any forward-looking statements after the date of this release, except as required by law.

**Media Contacts**

<br> Jonathan Keehner / Kate Thompson / Tanner Kaufman<br> Joele Frank, Wilkinson Brimmer Katcher<br> (212) 355-4449